Fellowship Director @UCDNephrology | Glomerular Disease Specialist | Director GN Clinic | @GlomCon Faculty and Editor | tweets=my own
- Tweets1.4K
- Following876
- Followers2.8K
- Likes5.5K
ALT Three panels showing the changes from baseline in 24-hour urinary protein-to-creatinine ratio. Panel A is a bar chart that shows the change from baseline in the 24-hour urinary protein-to-creatinine ratio at week 34 (primary end point). Panel B is a graph shows the change from baseline in the 24-hour urinary protein-to-creatinine ratio at weeks 10, 26, and 34; from the mixed model for repeated measures. Panel C is a bar chart that shows the percentage of patients with a 50% or greater reduction from baseline in the 24-hour urinary protein-to-creatinine ratio at weeks 10, 26, and 34.
ALT A bar chart from the Original Article "Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.” The trial name, RAINIER AIS-D08, is in parentheses after the title. The chart shows change in 24-hr urinary protein-to-creatinine ratio at week 36. The trial results are being presented at the American Society of Nephrology Kidney Week 2026. The logo of the New England Journal of Medicine is at the bottom.
ALT Two graphs showing the composite kidney end point (full analysis population). Panel A shows the least-squares mean change in the estimated glomerular filtration rate (eGFR) from baseline to 24 months, analyzed by the repeated-measures model, in the full analysis population, which included all patients who underwent randomization. Panel B shows the progression to a composite of kidney-function decline or kidney failure.
ALT A forest plot displaying the effectiveness of sibprernlimab versus placebo across various subgroups. Subgroups include demographic characteristics like age and race, as well as geographic region and stratification factors. Each subgroup is represented with bars indicating slope differences in ml/min/1.73 m² per year with 95% confidence intervals.
ALT A graph shows the mean change in the estimated glomerular filtration rate (GFR) from baseline through week 104 for atacicept and placebo.
ALT A graph from the Original Article " Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial.” The trial name, I CAN, is in parentheses after the title. The graph shows change in 24-hr urinary protein-to-creatinine ratio over time.” The trial results are being presented at the American Society of Nephrology Kidney Week 2026. The logo of the New England Journal of Medicine is at the bottom.
